MT. KISCO, N.Y., Oct. 13, 2015 (GLOBE NEWSWIRE) -- ImmuDyne, Inc. (OTCQB:IMMD), a health, wellness and skincare company commercializing a portfolio of proprietary topical and orally delivered products that rely on ImmuDyne’s patented and pure Yeast Beta Glucan ingredients, has entered into a semi-exclusive marketing agreement with Innate Scientific, LLC to launch a complete skin care regime that will be based primarily on strategic ingredients provided by ImmuDyne. Innate Scientific’s leadership team has deep experience in the direct marketing space and an impressive track record creating national brands expeditiously and profitably. Importantly, Innate Skincare’s founders have agreed to provide up to $2,000,000 in non-dilutive capital to finance direct marketing initiatives.
“As ImmuDyne has previously stated, we will continue to capitalize on our strong intellectual property portfolio and will aggressively pursue sales and marketing opportunities that are smart for our shareholders,” said Mark McLaughlin, President and CEO of ImmuDyne. “Innate Skincare brings to the table a proven and scalable direct-to-consumer business model that when combined with a highly desirable product will be very successful.”
Under the terms of the Agreement, ImmuDyne will own 51% of Innate Scientific, and anticipates this transaction to be accretive to 2015 revenue.
ImmuDyne has developed proprietary topical and oral delivery technologies, with several new market opportunities. The Company also manufactures and sells yeast beta-1,3/1,6 glucan for oral and topical uses. All of ImmuDyne’s Intellectual Property is protected by patents and/or trade secrets. ImmuDyne has offices located in Mt. Kisco, NY, Tampa, FL, and Florence, KY. Additional information can be found on the web at www.immudyne.com.
Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.
CONTACT: ImmuDyne, Inc. Mark McLaughlin: +1-914-714-8901